| HOME >> BIOLOGY >> TECHNOLOGY |
Marvin R. Garovoy, MD, Senior Vice President, Clinical Development, has held numerous industry positions over the past several years, including Vice President of Clinical Science at Xoma (US) LLC where he was the clinical lead working in collaboration with Genentech on the development of Raptiva(R) (efalizumab) from Phase I through FDA approval. Dr. Garovoy was most recently at Arriva Pharmaceuticals, where he held the position of Chief Medical Officer. Dr. Garovoy is a transplant physician by training, and has held multiple teaching positions at Harvard Medical School and at UCSF where he was Professor of Surgery, Medicine and Laboratory Medicine.
Sharron E. Gargosky, PhD, Chief Scientific Officer and Senior Vice
President of Corporate Development, was most recently Executive Director of
Ucyclyd, Research and Development at Ucyclyd Pharma Inc., a subsidiary of
Medicis Pharmaceutical Corporation. In this role, she was responsible for
the NDA approval of AMMONUL(R) (sodium phenylacetate and sodium benzoate)
Injection 10%/10%. Dr. Gargosky was previously Vice President of Business
Development for Diagnostic System Laboratories where she was responsible
for business expansion through evaluation and implementation of new growth
opportunities and patent portfolio management. Dr Gargosky's prior
positions include Clinical Director for Pharmacia and Assistant Research
Professor in the Endocrino
'/>"/>
| SOURCE Hyperion Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved |